FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to compound of formula (II), where Q represents S, dashed line represents double bond; R1 represents phenyl, pyrimidinyl, thienyl, indolyl; R2 represents phenyl; and each R3, R4 and R5 independently represent hydrogen, methyl, ethyl, nitro, cyano, F, Br, CF3, amino, OCH3; or to its pharmaceutically acceptable salt. Invention also relates to pharmaceutical compositions, possessing anti-cancer activity, which contain claimed compounds.
EFFECT: obtained are novel compounds, which can be applied in medicine for treating cancer, where cancer is selected from group, consisting of prostate cancer, breast cancer, ovary cancer, skin cancer, lung cancer, large intestine cancer, leukemia, kidney cancer, CNS cancer, and their combinations.
18 cl, 5 dwg, 5 tbl, 9 ex
Title | Year | Author | Number |
---|---|---|---|
COMPOUNDS FOR TREATING CANCER | 2010 |
|
RU2581367C2 |
COMPOUNDS FOR TREATING CANCER | 2011 |
|
RU2609018C2 |
COMPOUNDS FOR CANCER TREATMENT | 2011 |
|
RU2762111C1 |
COMPOUNDS FOR TREATMENT OF CANCER | 2015 |
|
RU2805949C2 |
COMPOUND FOR TREATING CANCER | 2014 |
|
RU2708247C2 |
COMPOUNDS FOR TREATING CANCER | 2015 |
|
RU2733393C2 |
COMPOUNDS FOR TREATING TRIPLE-NEGATIVE BREAST CANCER AND OVARIAN CANCER | 2019 |
|
RU2776897C2 |
INDOLE COMPOUNDS AS CELL NECROSIS INHIBITORS | 2008 |
|
RU2477282C2 |
MODULATORS OF HEC1 ACTIVITY AND METHODS THEREFOR | 2011 |
|
RU2576036C2 |
GLYCOLATOXIDASE INHIBITORS FOR THE TREATMENT OF DISEASES | 2018 |
|
RU2805308C2 |
Authors
Dates
2014-04-27—Published
2009-06-16—Filed